Donald C. Goff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Donald C. Goff has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
Oliver Freudenreich
8 shared publications- Jonathan M. Meyer
Department of Psychiatry, University of California, San Diego, CA, USA
6 shared publications - Thomas Scott Stroup
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York
6 shared publications - Henry A. Nasrallah
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH
5 shared publications - Joseph P. McEvoy
Duke University Medical Center, Durham, NC, USA
5 shared publications - Sonia M. Davis
A:Quintiles, Inc
5 shared publications
Latest Publications
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S80
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON NEGATIVE SYMPTOMS AND RELATED MRI INDICES
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S80
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON NEGATIVE SYMPTOMS AND RELATED MRI INDICES
- 1 August 2011
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 99 (2) , 245-253
The treatment of cognitive impairment in schizophrenia
- 1 August 2011
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 99 (2) , 245-253
The treatment of cognitive impairment in schizophrenia
- 1 July 2011
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 168 (7) , 667-9
Antipsychotic polypharmacy: are two ever better than one?
- 1 July 2011
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 168 (7) , 667-9
Antipsychotic polypharmacy: are two ever better than one?
- Open Access
- 1 May 2011
- Published by Elsevier in Schizophrenia Research
- Vol. 128 (1-3) , 166-170
The association between weight change and symptom reduction in the CATIE schizophrenia trial
- 1 May 2011
- Published by Elsevier in Schizophrenia Research
- Vol. 128 (1-3) , 166-170
Open AccessThe association between weight change and symptom reduction in the CATIE schizophrenia trial
- 1 December 2010
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 71 (suppl 2) , 20-26
Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder
Nonadherence with medication treatment is common but difficult to detect in patients with schizoaffective disorder and schizophrenia, almost half of whom take less than 70% of prescribed doses. Like patients in all areas of medicine, patients with schizoaffective disorder weigh the perceived benefits of medications against perceived disadvantages, but this process is complicated by their impaired insight, the stigma of the diagnosis, and the often troubling side effects of antipsychotic medication. Interventions to improve adherence include encouraging acceptance of the illness, drawing analogies with treatment for chronic medical disease, and involving the patient in decision making. Clinicians must remain nonjudgmental, encouraging patients to disclose problems with adherence and anticipating that improvement in adherence may require a prolonged effort. Selection of antipsychotic medication is critical to avoid adverse side effects, and some medications may provide a sense of well-being, such as improvement in insomnia, anxiety, or depression. Depot (rather than oral) antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received, which can be used for purposes of dose adjustments or to guide response to relapse.
- 1 December 2010
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 71 (suppl 2) , 20-26
Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder
Nonadherence with medication treatment is common but difficult to detect in patients with schizoaffective disorder and schizophrenia, almost half of whom take less than 70% of prescribed doses. Like patients in all areas of medicine, patients with schizoaffective disorder weigh the perceived benefits of medications against perceived disadvantages, but this process is complicated by their impaired insight, the stigma of the diagnosis, and the often troubling side effects of antipsychotic medication. Interventions to improve adherence include encouraging acceptance of the illness, drawing analogies with treatment for chronic medical disease, and involving the patient in decision making. Clinicians must remain nonjudgmental, encouraging patients to disclose problems with adherence and anticipating that improvement in adherence may require a prolonged effort. Selection of antipsychotic medication is critical to avoid adverse side effects, and some medications may provide a sense of well-being, such as improvement in insomnia, anxiety, or depression. Depot (rather than oral) antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received, which can be used for purposes of dose adjustments or to guide response to relapse.
- 1 April 2010
- Published by Cambridge University Press (CUP)
- p. 173-188
Metabolic side effects and risk of cardiovascular disease
This chapter presents the rationale for the primary effectiveness outcome and results for the randomized phases of the study. Effectiveness studies of any treatments for a chronic disease such as schizophrenia must incorporate a longer term view of the treatments' effects. A primary goal of such effectiveness studies is to determine the durability of the treatments. These studies examine whether the treatments continue to provide therapeutic benefit over the course of illness. To ensure maximum generalizability, few patients should be excluded from effectiveness studies. As symptom reduction remains an important goal of antipsychotic treatment and is the typical outcome in antipsychotic drug trials, the chapter discusses the results of how olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone compared in their effects on the core psychopathology of schizophrenia. CATIE findings on effectiveness and symptom reduction are consistent with many careful meta-analyses.
- 1 April 2010
- Published by Cambridge University Press (CUP)
- p. 173-188
Metabolic side effects and risk of cardiovascular disease
This chapter presents the rationale for the primary effectiveness outcome and results for the randomized phases of the study. Effectiveness studies of any treatments for a chronic disease such as schizophrenia must incorporate a longer term view of the treatments' effects. A primary goal of such effectiveness studies is to determine the durability of the treatments. These studies examine whether the treatments continue to provide therapeutic benefit over the course of illness. To ensure maximum generalizability, few patients should be excluded from effectiveness studies. As symptom reduction remains an important goal of antipsychotic treatment and is the typical outcome in antipsychotic drug trials, the chapter discusses the results of how olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone compared in their effects on the core psychopathology of schizophrenia. CATIE findings on effectiveness and symptom reduction are consistent with many careful meta-analyses.
- 1 January 2010
- Published by Elsevier in Psiquiatría Biológica
- Vol. 17 (1) , 22-31
La memoria de extinción está deteriorada en la esquizofrenia
- 1 January 2010
- Published by Elsevier in Psiquiatría Biológica
- Vol. 17 (1) , 22-31
La memoria de extinción está deteriorada en la esquizofrenia
- 1 December 2009
- Published by Elsevier in Biological Psychiatry
- Vol. 66 (11) , 1013-1022
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study
- 1 December 2009
- Published by Elsevier in Biological Psychiatry
- Vol. 66 (11) , 1013-1022
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study
- 3 August 2009
- Published by Springer Nature
- p. 209-238
Rating Scales in Schizophrenia
- 1 December 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 106 (2-3) , 320-327
Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
- 1 December 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 106 (2-3) , 320-327
Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study